Drug

Orvepitant

Status:
Phase 2
Condition:
Chronic Cough
Intervention Type:
Oral Drug
Funder Type:
Industry

Drug Details

Orvepitant is a neurokinin-1 receptor antagonist.

Study Purpose

ORV-PF-01 is a two-way, placebo-controlled, crossover study to evaluate the effect of two doses of orvepitant on cough in patients with IPF.

This drug has no clinical trials actively recruiting patients at this time.